This is training exercise designed to bring HIV vaccine research information to life.
AIDS Vaccine Science: What’s all the buzz about?
Good Participatory Practice: Guidelines for TB Drug Trials
The Good Participatory Practice (GPP) guidelines for TB Drug Trials is the product of a collaboration between AVAC and the Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens. The guidelines offer trial funders, sponsors, and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle. This first edition, published in 2012, contains five sections that provide context, foundational principles, and key practices for conducting TB drug trials.
GPP Overview PowerPoint
The GPP Overview PowerPoint contains 35 slides that users can draw from when introducing the Good Participatory Practice guidelines. The PowerPoint contains slides on the history and content of the guidelines, who the intended user is, the role and importance of GPP in the field and strategies for effective use. The slide deck is broken into sections allowing slides can be rearranged or deleted to make a complete presentation.
Stakeholder Engagement Toolkit for HIV Prevention Trials
The Stakeholder Engagement Toolkit for HIV Prevention Trials, developed by FHI360, is a guide to engaging a wide range of key stakeholders throughout the trial lifecycle. The toolkit is based on best practices and experience of clinical trial experts and community-based advocates. It includes short case studies, tools to guide and chart progress during a trial, stakeholder identification tools and other useful documents to document work tasks and define successful engagement in terms of the local context.
African Women’s Civil Society Consultation on HIV Risk and Hormonal Contraceptives
More than 40 women representing HIV prevention advocates, reproductive health service providers, and women living with HIV from Kenya, South Africa, Rwanda, Uganda and Zimbabwe met to review and discuss the existing data on hormonal contraceptive use and HIV risk.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Research: An overview
This series of infographics highlights the current state of the field. Each research area is expanded with key details about the current focus and advancements in the science along with critical issues that advocates should be tracking.
HIV Vaccines by the Numbers: Trials, discoveries, money and more
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphics represents key facts about the AIDS vaccine field.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
AIDS Vaccine Science for Busy Advocates – RV144: Building on a breakthrough
A one-page document describing RV144, the first AIDS vaccine trial to show protection against HIV in humans, and plans to further this research.